The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1435
ISSUE 1435
February 3, 2014
Issue 1435
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Perampanel (Fycompa) for Epilepsy
February 3, 2014 (Issue: 1435)
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has
been approved by the FDA for adjunctive treatment of
partial-onset seizures in patients ≥12 years old. New
drugs for epilepsy are...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.